US Physical Therapy (USPH) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
13 May, 2026Executive summary
Q1 2026 net revenue grew 7.9% year-over-year to $198.3 million, driven by both physical therapy and industrial injury prevention segments.
Net income attributable to shareholders was $5.0 million, down from $9.9 million in Q1 2025, impacted by a $2.0 million loss on contingent earn-out revaluation and higher corporate costs.
Adjusted EBITDA rose to $20.2 million from $19.5 million year-over-year.
Patient volume increased 6.9% year-over-year, with daily visits per clinic rising to 31.8.
Strategic initiatives include front desk virtualization, AI-assisted documentation, remote monitoring, and expansion of hospital alliances.
Financial highlights
Physical therapy net revenue was $167.7 million, up 7.2% year-over-year; industrial injury prevention revenue was $30.6 million, up 11.8%.
Net patient revenue per visit increased to $106.49.
Adjusted EBITDA margin was 13.1% in Q1 2026 versus 13.7% in Q1 2025.
Gross profit increased 5.4% to $32.8 million, but gross margin declined to 16.5% from 16.9% year-over-year.
Earnings per share was a loss of $0.12, compared to earnings of $0.80 in Q1 2025, due to non-cash adjustments for redeemable non-controlling interests.
Outlook and guidance
Full-year 2026 adjusted EBITDA guidance reaffirmed at $102–$106 million.
Guidance includes partial year impact of two new hospital affiliations and Medicare rate increase.
Hospital alliances expected to add at least $7.3 million in annualized EBITDA upon full integration.
Management expects continued growth through acquisitions and new clinic development.
Additional acquisitions and hospital alliances not yet included in guidance could provide further upside.
Latest events from US Physical Therapy
- Strong organic and acquisition-driven growth, with Medicare rate tailwinds and expanding high-margin segments.USPH
The 15th Annual East Coast IDEAS Conference9 Jul 2026 - Record patient volumes and revenue growth, but net income and margins pressured by labor costs.USPH
Q2 20248 Jul 2026 - Q3 2024 delivered record patient volumes, 12% revenue growth, and major portfolio optimization.USPH
Q3 20248 Jul 2026 - Record Q1 patient volume, 18.1% revenue, and 23% net income growth, fueled by acquisitions.USPH
Q1 20258 Jul 2026 - Proxy seeks approval for directors, executive pay, auditor, and highlights governance and ESG.USPH
Proxy filing16 Apr 2026 - Record 2025 growth and new alliances position for higher 2026 EBITDA and continued expansion.USPH
Q4 20259 Mar 2026 - Double-digit growth and high-margin expansion in injury prevention drive strong performance.USPH
16th Annual Midwest Ideas Conference3 Feb 2026 - Growth continues via partnerships, acquisitions, and injury prevention despite reimbursement headwinds.USPH
15th Annual Midwest IDEAS Investor Conference23 Jan 2026 - Growth through strategic acquisitions and partnerships drives strong performance and expansion.USPH
2024 Southwest IDEAS Conference13 Jan 2026